Therapeutic potential of midkine in cardiovascular disease

Ischaemic heart disease, stroke and their pathological consequences are life‐threatening conditions that account for about half of deaths in developed countries. Pathology of these diseases includes cell death due to ischaemia/reperfusion injury, vascular stenosis and cardiac remodelling. The growth factor midkine plays a pivotal role in these events. Midkine shows an acute cytoprotective effect in ischaemia/reperfusion injury at least in part via its anti‐apoptotic effect. Moreover, while midkine promotes endothelial cell proliferation, it also recruits inflammatory cells to lesions. These activities eventually enhance angiogenesis, thereby preventing cardiac tissue remodelling. However, midkine's activity in recruiting inflammatory cells into the vascular wall also triggers neointima formation, and consequently, vascular stenosis. Moreover, midkine is induced in cancer tissues where it enhances angiogenesis. Therefore, midkine may promote tumour formation through its angiogenic and anti‐apoptotic activity. This review focuses on the roles of midkine in ischaemic cardiovascular disease and their pathological consequences, that is angiogenesis, vascular stenosis, and cardiac remodelling, and discusses the possible therapeutic potential of modulation of midkine in these diseases.

[1]  E. Ekizoğlu.  Current Therapies in Ischemic Stroke , 2016 .

[2]  Stanley Silverman,et al.  The role of monocytes in angiogenesis and atherosclerosis. , 2014, Journal of the American College of Cardiology.

[3]  S. Kishida,et al.  The heparin-binding growth factor midkine: the biological activities and candidate receptors. , 2013, Journal of biochemistry.

[4]  A. Malik,et al.  Transcriptional regulation of endothelial cell and vascular development. , 2013, Circulation research.

[5]  K. Hirschi,et al.  Regulation of endothelial cell differentiation and specification. , 2013, Circulation research.

[6]  L. V. Van Laake,et al.  Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. , 2013, Cardiovascular research.

[7]  R. McLendon,et al.  Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth , 2013, Cell.

[8]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[9]  Yoshikazu Nakamura,et al.  Midkine promotes neuroblastoma through Notch2 signaling. , 2013, Cancer research.

[10]  A. Sica,et al.  Macrophage plasticity and polarization in tissue repair and remodelling , 2013, The Journal of pathology.

[11]  Yoon-Jae Cho,et al.  The VEGF pathway in cancer and disease: responses, resistance, and the path forward. , 2012, Cold Spring Harbor perspectives in medicine.

[12]  A. Marom,et al.  Regulation of CLL survival by hypoxia‐inducible factor and its target genes , 2012, FEBS letters.

[13]  M. Shakibaei,et al.  Midkine acts as proangiogenic cytokine in hypoxia-induced angiogenesis. , 2012, American journal of physiology. Heart and circulatory physiology.

[14]  E. Trinka,et al.  Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies. , 2012, Drug discovery today.

[15]  L. Claesson-Welsh.  Blood vessels as targets in tumor therapy , 2012, Upsala journal of medical sciences.

[16]  Yu Jin Lee,et al.  Midkine prevented hypoxic injury of mouse embryonic stem cells through activation of Akt and HIF‐1α via low‐density lipoprotein receptor‐related protein‐1 , 2012, Journal of cellular physiology.

[17]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[18]  L. Leng,et al.  The Cytokine Midkine and Its Receptor RPTPζ Regulate B Cell Survival in a Pathway Induced by CD74 , 2012, The Journal of Immunology.

[19]  H. Masuda,et al.  R EGENERATIVE M EDICINE Concise Review: Circulating Endothelial Progenitor Cells for Vascular Medicine , 2022 .

[20]  T. Opthof,et al.  A Single Intracoronary Injection of Midkine Reduces Ischemia/Reperfusion Injury in Swine Hearts: A Novel Therapeutic Approach for Acute Coronary Syndrome , 2011, Front. Physio..

[21]  K. Moore,et al.  Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.

[22]  Y. Kodera,et al.  Premature Ligand-Receptor Interaction during Biosynthesis Limits the Production of Growth Factor Midkine and Its Receptor LDL Receptor-related Protein 1* , 2011, The Journal of Biological Chemistry.

[23]  Edward S. Kim,et al.  Bevacizumab: current updates in treatment , 2010, Current opinion in oncology.

[24]  H. Jono,et al.  Midkine expression in malignant salivary gland tumors and its role in tumor angiogenesis. , 2010, Oral oncology.

[25]  T. Muramatsu.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases , 2010, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[26]  S. Ibayashi,et al.  Midkine gene transfer protects against focal brain ischemia and augments neurogenesis , 2009, Journal of the Neurological Sciences.

[27]  A. Grothey,et al.  Targeting angiogenesis: progress with anti-VEGF treatment with large molecules , 2009, Nature Reviews Clinical Oncology.

[28]  C. Lewis,et al.  Neutrophils: key mediators of tumour angiogenesis , 2009, International journal of experimental pathology.

[29]  I. Kodama,et al.  Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction. , 2009, American journal of physiology. Heart and circulatory physiology.

[30]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[31]  K. Komori,et al.  Pitavastatin inhibits intimal hyperplasia in rabbit vein graft. , 2008, The Journal of surgical research.

[32]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[33]  K. Komori,et al.  Midkine is expressed by infiltrating macrophages in in-stent restenosis in hypercholesterolemic rabbits. , 2008, Journal of vascular surgery.

[34]  N. Matsuura,et al.  Therapeutic effect of midkine on cardiac remodeling in infarcted rat hearts. , 2008, The Annals of thoracic surgery.

[35]  P. Ferdinandy,et al.  Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning , 2007, Pharmacological Reviews.

[36]  Dai Fukumura,et al.  Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize , 2007, Journal of cellular biochemistry.

[37]  X. Yao,et al.  Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis. , 2007, World journal of gastroenterology.

[38]  T. Ji,et al.  Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. , 2007, International journal of oral and maxillofacial surgery.

[39]  K. Kamiya,et al.  Midkine Plays a Protective Role Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Apoptotic Reaction , 2006, Circulation.

[40]  K. Komori,et al.  Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. , 2006, Journal of vascular surgery.

[41]  T. Muramatsu,et al.  Midkine, a heparin-binding growth factor, produced by the host enhances metastasis of Lewis lung carcinoma cells. , 2006, Cancer letters.

[42]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[43]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[44]  K. Komori,et al.  Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury. , 2005, American journal of physiology. Heart and circulatory physiology.

[45]  S. Ibayashi,et al.  Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia , 2005, Gene Therapy.

[46]  D. McDonald,et al.  Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.

[47]  Yun Wang,et al.  Midkine and retinoic acid reduce cerebral infarction induced by middle cerebral artery ligation in rats , 2004, Neuroscience Letters.

[48]  P. Reynolds,et al.  Midkine Is Regulated by Hypoxia and Causes Pulmonary Vascular Remodeling* , 2004, Journal of Biological Chemistry.

[49]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[50]  H. Miyake,et al.  Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  Richard G. W. Anderson,et al.  LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis , 2003, Science.

[52]  M. Hirai,et al.  Nuclear Targeting by the Growth Factor Midkine , 2002, Molecular and Cellular Biology.

[53]  C. Powers,et al.  Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types* , 2002, The Journal of Biological Chemistry.

[54]  T. Muramatsu,et al.  Midkine, a heparin-binding growth factor, promotes growth and glycosaminoglycan synthesis of endothelial cells through its action on smooth muscle cells in an artificial blood vessel model. , 2002, Journal of cell science.

[55]  M. Noda,et al.  Haptotactic Migration Induced by Midkine , 2001, The Journal of Biological Chemistry.

[56]  G. Mashour,et al.  The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells , 2001, Oncogene.

[57]  K. Zou,et al.  LDL receptor-related protein as a component of the midkine receptor. , 2000, Biochemical and biophysical research communications.

[58]  Y. Yuzawa,et al.  Neointima formation in a restenosis model is suppressed in midkine-deficient mice. , 2000, The Journal of clinical investigation.

[59]  T. Muramatsu,et al.  Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of Bcl-2 expression by Midkine. , 2000, Journal of biochemistry.

[60]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[61]  M. Noda,et al.  A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. , 1999, The Journal of biological chemistry.

[62]  T. Muramatsu,et al.  Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. , 1997, Journal of biochemistry.

[63]  S. Donnini,et al.  An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. , 1997, Cancer research.

[64]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[65]  A. Harris,et al.  The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. , 1996, Cancer research.

[66]  T J Poole,et al.  Vasculogenesis and angiogenesis: two distinct morphogenetic mechanisms establish embryonic vascular pattern. , 1989, The Journal of experimental zoology.

[67]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[68]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[69]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[70]  L. Ricci-Vitiani,et al.  Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.

[71]  佐藤 和一.  Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury , 2002 .

[72]  Aldons J. Lusis,et al.  Atherosclerosis : Vascular biology , 2000 .